20/20 Biolabs, Inc. Common Stock Cash Flow Conversion Efficiency
20/20 Biolabs, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has a cash flow conversion efficiency ratio of -0.350x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-536.45K) by net assets ($1.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 20/20 Biolabs, Inc. Common Stock (2016–2024)
Cash flow conversion efficiency of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. This chart illustrates how 20/20 Biolabs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AIDX live share price for real-time trading data and today's change.
20/20 Biolabs, Inc. Common Stock Cash Flow Conversion Ratio Explained
20/20 Biolabs, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
20/20 Biolabs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see AIDX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smiths News PLC
LSE:SNWS
|
2.916x |
|
Bioatla Inc
NASDAQ:BCAB
|
0.141x |
|
Henry Boot PLC
LSE:BOOT
|
-0.039x |
|
UMT United Mobility Technology AG
XETRA:UMD
|
0.141x |
|
Geekco Technologies Corp
V:GKO
|
0.017x |
|
GENERIC GOLD CORP.
F:1WD
|
N/A |
|
Rocky Mountain Liquor Inc
V:RUM
|
0.030x |
|
Iveda Solutions Inc
NASDAQ:IVDA
|
-0.053x |
Annual Cash Flow Conversion Efficiency for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. Review 20/20 Biolabs, Inc. Common Stock free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.53 Million | $-2.60 Million | -1.694x | -56.91% |
| 2023-12-31 | $4.29 Million | $-4.63 Million | -1.080x | -274.38% |
| 2022-12-31 | $9.37 Million | $5.80 Million | 0.619x | +497.12% |
| 2021-12-31 | $6.89 Million | $-1.07 Million | -0.156x | +74.07% |
| 2020-12-31 | $3.39 Million | $-2.04 Million | -0.601x | +39.14% |
| 2019-12-31 | $2.15 Million | $-2.12 Million | -0.988x | -146.80% |
| 2018-12-31 | $3.28 Million | $-1.31 Million | -0.400x | +82.79% |
| 2017-12-31 | $456.18K | $-1.06 Million | -2.325x | +3.73% |
| 2016-12-31 | $784.36K | $-1.89 Million | -2.415x | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more